# A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch

> **NCT03778047** · PHASE1 · COMPLETED · sponsor: **Hinova Pharmaceuticals Inc.** · enrollment: 10 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** HC1119

## Key facts

- **NCT ID:** NCT03778047
- **Lead sponsor:** Hinova Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-07
- **Primary completion:** 2018-10-24
- **Final completion:** 2019-08-28
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03778047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03778047, "A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03778047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*